​

Insulet (PODD) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

PODD Stock Forecast

Insulet (PODD) stock forecast, based on 50 Wall Street analysts, predicts a 12-month average price target of $246.17, with a high of $400.00 and a low of $198.00. This represents a 65.39% increase from the last price of $148.84.

$100 $160 $220 $280 $340 $400 High: $400 Avg: $246.17 Low: $198 Last Closed Price: $148.84

PODD Stock Rating

Insulet stock's rating consensus is Buy, based on 50 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 35 Buy (70.00%), 12 Hold (24.00%), 3 Sell (6.00%), and 0 Strong Sell (0.00%).

Buy
Total 50 0 3 12 35 Strong Sell Sell Hold Buy Strong Buy

PODD Price Target Upside V Benchmarks

TypeNameUpside
StockInsulet65.39%
SectorHealthcare Stocks 15.45%
IndustryMedical Device Stocks39.47%

Price Target Trends

1M3M12M
# Anlaysts122037
Avg Price Target$239.08$278.55$324.03
Last Closing Price$148.84$148.84$148.84
Upside/Downside60.63%87.15%117.70%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
May, 265153-124
Apr, 265171-124
Mar, 266181-126
Feb, 266181-126
Jan, 265192--26
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 07, 2026Goldman Sachs$237.00$160.4047.76%59.23%
May 07, 2026Shagun SinghRBC Capital$280.00$161.1073.81%88.12%
May 07, 2026Richard NewitterTruist Financial$250.00$157.3058.93%67.97%
May 07, 2026Evercore ISI$200.00$156.7027.63%34.37%
May 07, 2026Oppenheimer$210.00$151.2838.82%41.09%
May 07, 2026Stifel Nicolaus$250.00$151.2865.26%67.97%
May 07, 2026William PlovanicCanaccord Genuity$249.00$151.2864.60%67.29%
May 07, 2026Bernstein$200.00$151.2832.21%34.37%
May 07, 2026Matt MiksicBarclays$198.00$151.2830.88%33.03%
May 06, 2026BTIG$260.00$152.6770.30%74.68%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 12, 2026BenchmarkBuyinitialise
May 07, 2026RBC CapitalOutperformOutperformhold
May 07, 2026BarclaysUnderweightUnderweighthold
May 06, 2026CitigroupNeutralNeutralhold
Apr 14, 2026RBC CapitalOutperformOutperformhold
Feb 19, 2026Goldman SachsBuyBuyhold
Feb 19, 2026BarclaysUnderweightUnderweighthold
Feb 18, 2026Canaccord GenuityBuyBuyhold
Feb 18, 2026BTIGBuyBuyhold
Jan 26, 2026Cowen & Co.BuyHolddowngrade

Financial Forecast

EPS Forecast

$0 $1 $2 $3 $4 $5 $6 $7 $8 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.25$0.07$2.96$5.97$3.51---
Avg Forecast$0.13$0.42$1.99$3.21$3.93$4.95$5.96$7.30
High Forecast$0.13$0.43$2.08$3.36$4.30$5.68$6.79$7.55
Low Forecast$0.13$0.41$1.86$3.11$3.71$3.58$4.76$7.08
Surprise %92.31%-83.33%48.74%85.98%-10.69%---

Revenue Forecast

$1B $2B $2B $3B $3B $4B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.10B$1.31B$1.70B$2.07B$2.71B---
Avg Forecast$1.09B$1.27B$1.65B$2.06B$2.43B$2.86B$3.32B$3.75B
High Forecast$1.11B$1.30B$1.69B$2.11B$2.49B$2.86B$3.35B$3.85B
Low Forecast$1.07B$1.24B$1.64B$2.05B$2.40B$2.85B$3.28B$3.67B
Surprise %0.66%2.88%2.96%0.71%11.33%---

Net Income Forecast

$-150M $0 $150M $300M $450M $600M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$16.80M$4.60M$206.30M$418.30M$247.10M---
Avg Forecast$4.65M$-70.49M$206.30M$238.15M$289.34M$368.31M$434.07M$537.52M
High Forecast$17.25M$-30.76M$322.59M$247.32M$316.29M$418.31M$499.77M$555.71M
Low Forecast$-7.94M$-110.23M$90.01M$228.97M$273.53M$263.30M$350.38M$521.49M
Surprise %261.00%-106.53%-75.65%-14.60%---

PODD Forecast FAQ

Is Insulet stock a buy?

Insulet stock has a consensus rating of Buy, based on 50 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 35 Buy, 12 Hold, 3 Sell, and 0 Strong Sell, reflecting a consensus that Insulet is a favorable investment for most analysts.

What is Insulet's price target?

Insulet's price target, set by 50 Wall Street analysts, averages $246.17 over the next 12 months. The price target range spans from $198 at the low end to $400 at the high end, suggesting a potential 65.39% change from the previous closing price of $148.84.

How does Insulet stock forecast compare to its benchmarks?

Insulet's stock forecast shows a 65.39% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the medical device stocks industry (39.47%).

What is the breakdown of analyst ratings for Insulet over the past three months?

  • May 2026: 20.83% Strong Buy, 62.50% Buy, 12.50% Hold, 0% Sell, 4.17% Strong Sell.
  • April 2026: 20.83% Strong Buy, 70.83% Buy, 4.17% Hold, 0% Sell, 4.17% Strong Sell.
  • March 2026: 23.08% Strong Buy, 69.23% Buy, 3.85% Hold, 0% Sell, 3.85% Strong Sell.

What is Insulet’s EPS forecast?

Insulet's average annual EPS forecast for its fiscal year ending in December 2026 is $4.95, marking a 41.03% increase from the reported $3.51 in 2025. Estimates for the following years are $5.96 in 2027, and $7.3 in 2028.

What is Insulet’s revenue forecast?

Insulet's average annual revenue forecast for its fiscal year ending in December 2026 is $2.86B, reflecting a 5.51% increase from the reported $2.71B in 2025. The forecast for 2027 is $3.32B, and $3.75B for 2028.

What is Insulet’s net income forecast?

Insulet's net income forecast for the fiscal year ending in December 2026 stands at $368.31M, representing an 49.05% increase from the reported $247.1M in 2025. Projections indicate $434.07M in 2027, and $537.52M in 2028.